Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion

This Phase IV interventional trial (n=60) aims to investigate the effectiveness of intraoperative ketamine in reducing postoperative depressive symptoms in patients undergoing lumbo-peritoneal shunt insertion.

Conducted by Benha University in Egypt, the study focuses on patients aged 20 to 44 years with moderate to severe depressive symptoms and an expected hospital stay of at least 7 days. Participants will be randomly assigned to receive either ketamine or normal saline as a placebo during the procedure.

The primary outcome measure is the rate of response to treating postoperative depression, defined as a relative reduction of more than 50% from the baseline 10-item MADRS score at 3 postoperative days. Secondary outcome measures include the remission rate, incidence of severe pain, and quality of life within the first 48 hours postoperatively.

The study aims to assess whether intraoperative ketamine administration can effectively alleviate postoperative depressive symptoms in patients undergoing lumbar-peritoneal shunt insertion, potentially improving patient outcomes and quality of life.

Topic Depression
Compound Placebo Ketamine
Country Egypt
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.